Literature DB >> 2056122

Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation.

M F Linton1, R Gish, S T Hubl, E Bütler, C Esquivel, W I Bry, J K Boyles, M R Wardell, S G Young.   

Abstract

Apolipoprotein (apo) E and the two B apolipoproteins, apoB48 and apoB100, are important proteins in human lipoprotein metabolism. Commonly occurring polymorphisms in the genes for apoE and apoB result in amino acid substitutions that produce readily detectable phenotypic differences in these proteins. We studied changes in apoE and apoB phenotypes before and after liver transplantation to gain new insights into apolipoprotein physiology. In all 29 patients that we studied, the postoperative serum apoE phenotype of the recipient, as assessed by isoelectric focusing, converted virtually completely to that of the donor, providing evidence that greater than 90% of the apoE in the plasma is synthesized by the liver. In contrast, the cerebrospinal fluid apoE phenotype did not change to the donor's phenotype after liver transplantation, indicating that most of the apoE in CSF cannot be derived from the plasma pool and therefore must be synthesized locally. The apoB100 phenotype (assessed with immunoassays using monoclonal antibody MB19, an antibody that detects a two-allele polymorphism in apoB) invariably converted to the phenotype of the donor. In four normolipidemic patients, we determined the MB19 phenotype of both the apoB100 and apoB48 in the "chylomicron fraction" isolated from plasma 3 h after a fat-rich meal. Interestingly, the apoB100 in the chylomicron fraction invariably had the phenotype of the donor, indicating that the vast majority of the large, triglyceride-rich apoB100-containing lipoproteins that appear in the plasma after a fat-rich meal are actually VLDL of hepatic origin. The MB19 phenotype of the apoB48 in the plasma chylomicron fraction did not change after liver transplantation, indicating that almost all of the apoB48 in plasma chylomicrons is derived from the intestine. These results were consistent with our immunocytochemical studies on intestinal biopsy specimens of organ donors; using apoB-specific monoclonal antibodies, we found evidence for apoB48, but not apoB100, in donor intestinal biopsy specimens.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2056122      PMCID: PMC296029          DOI: 10.1172/JCI115288

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  50 in total

1.  The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum.

Authors:  R J HAVEL; H A EDER; J H BRAGDON
Journal:  J Clin Invest       Date:  1955-09       Impact factor: 14.808

2.  Apoprotein (E--A-II) complex of human plasma lipoproteins. I. Characterization of this mixed disulfide and its identification in a high density lipoprotein subfraction.

Authors:  K H Weisgraber; R W Mahley
Journal:  J Biol Chem       Date:  1978-09-10       Impact factor: 5.157

Review 3.  Changing concepts: liver replacement for hereditary tyrosinemia and hepatoma.

Authors:  T E Starzl; B J Zitelli; B W Shaw; S Iwatsuki; J C Gartner; R D Gordon; J J Malatuck; I J Fox; A H Urbach; D H Van Thiel
Journal:  J Pediatr       Date:  1985-04       Impact factor: 4.406

4.  Apolipoproteins in human cerebrospinal fluid.

Authors:  P S Roheim; M Carey; T Forte; G L Vega
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

5.  Biochemical and genetic studies of the apoprotein E secreted by mouse macrophages and human monocytes.

Authors:  S K Basu; Y K Ho; M S Brown; D W Bilheimer; R G Anderson; J L Goldstein
Journal:  J Biol Chem       Date:  1982-08-25       Impact factor: 5.157

6.  Heterogeneity of apolipoprotein B: isolation of a new species from human chylomicrons.

Authors:  J P Kane; D A Hardman; H E Paulus
Journal:  Proc Natl Acad Sci U S A       Date:  1980-05       Impact factor: 11.205

7.  Parallel expression of the MB19 genetic polymorphism in apoprotein B-100 and apoprotein B-48. Evidence that both apoproteins are products of the same gene.

Authors:  S G Young; S J Bertics; T M Scott; B W Dubois; L K Curtiss; J L Witztum
Journal:  J Biol Chem       Date:  1986-03-05       Impact factor: 5.157

8.  Apoprotein synthesis by human duodenojejunal mucosa.

Authors:  D Rachmilewitz; J J Albers; D R Saunders; M Fainaru
Journal:  Gastroenterology       Date:  1978-10       Impact factor: 22.682

9.  Apolipoprotein E gene mapping and expression: localization of the structural gene to human chromosome 19 and expression of ApoE mRNA in lipoprotein- and non-lipoprotein-producing tissues.

Authors:  Y C Lin-Lee; F T Kao; P Cheung; L Chan
Journal:  Biochemistry       Date:  1985-07-02       Impact factor: 3.162

10.  Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system.

Authors:  J K Boyles; R E Pitas; E Wilson; R W Mahley; J M Taylor
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

View more
  101 in total

1.  Expression of human apolipoprotein E3 or E4 in the brains of Apoe-/- mice: isoform-specific effects on neurodegeneration.

Authors:  M Buttini; M Orth; S Bellosta; H Akeefe; R E Pitas; T Wyss-Coray; L Mucke; R W Mahley
Journal:  J Neurosci       Date:  1999-06-15       Impact factor: 6.167

2.  ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis.

Authors:  Anne M Fagan; Erin Christopher; Jennie W Taylor; Maia Parsadanian; Michael Spinner; Melanie Watson; John D Fryer; Suzanne Wahrle; Kelly R Bales; Steven M Paul; David M Holtzman
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

3.  Plasma biomarkers for neuronal ceroid lipofuscinosis.

Authors:  Samantha L Hersrud; Ryan D Geraets; Krystal L Weber; Chun-Hung Chan; David A Pearce
Journal:  FEBS J       Date:  2015-12-17       Impact factor: 5.542

4.  Hormonal modulators of glial ABCA1 and apoE levels.

Authors:  Jianjia Fan; Yoko Shimizu; Jeniffer Chan; Anna Wilkinson; Ayaka Ito; Peter Tontonoz; Edie Dullaghan; Liisa A M Galea; Tom Pfeifer; Cheryl L Wellington
Journal:  J Lipid Res       Date:  2013-09-02       Impact factor: 5.922

Review 5.  Proposed mechanism for lipoprotein remodelling in the brain.

Authors:  Chunjiang Yu; Katherine L Youmans; Mary J LaDu
Journal:  Biochim Biophys Acta       Date:  2010-05-12

6.  COG1410, a novel apolipoprotein-E mimetic, improves functional and morphological recovery in a rat model of focal brain ischemia.

Authors:  Elena A Tukhovskaya; Alexey Yu Yukin; Oksana N Khokhlova; Arkady N Murashev; Michael P Vitek
Journal:  J Neurosci Res       Date:  2009-02-15       Impact factor: 4.164

Review 7.  The role of apolipoprotein E in Guillain-Barré syndrome and experimental autoimmune neuritis.

Authors:  Hong-liang Zhang; Jiang Wu; Jie Zhu
Journal:  J Biomed Biotechnol       Date:  2010-02-16

8.  Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice.

Authors:  S Bellosta; R W Mahley; D A Sanan; J Murata; D L Newland; J M Taylor; R E Pitas
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

9.  Diet and age interactions with regards to cholesterol regulation and brain pathogenesis.

Authors:  Romina M Uranga; Jeffrey N Keller
Journal:  Curr Gerontol Geriatr Res       Date:  2010-04-11

Review 10.  The immune-modulatory role of apolipoprotein E with emphasis on multiple sclerosis and experimental autoimmune encephalomyelitis.

Authors:  Hong-Liang Zhang; Jiang Wu; Jie Zhu
Journal:  Clin Dev Immunol       Date:  2010-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.